A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Sputum after Challenge with Inhaled Lipopolysaccharide (LPS)
Latest Information Update: 08 Aug 2019
At a glance
- Drugs AZD 8309 (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Pharmacodynamics
- Sponsors AstraZeneca AB
Most Recent Events
- 08 Aug 2019 New trial record